Rocket Pharmaceuticals Inc RCKT.OQ RCKT.O is expected to show a rise in quarterly revenue when it reports results on November 5 (estimated) for the period ending September 30 2025
The Cranbury New Jersey-based company is expected to report revenue of $277.78 thousand, according to the mean estimate from 9 analysts, based on LSEG data.
LSEG's mean analyst estimate for Rocket Pharmaceuticals Inc is for a loss of 50 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 7 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Rocket Pharmaceuticals Inc is $7.50, about 49.7% above its last closing price of $3.77
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.55 | -0.56 | -0.59 | Missed | -6 |
Mar. 31 2025 | -0.59 | -0.61 | -0.56 | Beat | 8.8 |
Dec. 31 2024 | -0.71 | -0.72 | -0.62 | Beat | 13.6 |
Sep. 30 2024 | -0.75 | -0.76 | -0.71 | Beat | 6.6 |
Jun. 30 2024 | -0.71 | -0.72 | -0.74 | Missed | -3.2 |
Mar. 31 2024 | -0.66 | -0.68 | -0.66 | Beat | 3.1 |
Dec. 31 2023 | -0.77 | -0.79 | -0.64 | Beat | 18.6 |
Sep. 30 2023 | -0.78 | -0.81 | -0.75 | Beat | 7.2 |
This summary was machine generated November 3 at 11:05 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments